An investigation has revealed significant risks associated with the online prescribing of slimming tablets, highlighting gaps in pharmacy verification processes that could put vulnerable individuals in danger. The inquiry focused on the recently launched pill form of Wegovy, a weight-loss medication that reduces appetite by mimicking the hormone GLP-1. Though intended for people with severe obesity or related medical conditions, the drug is being obtained through online pharmacies without proper safeguards.
Under regulations from the General Pharmaceutical Council, pharmacies are required to verify a patient’s body mass index (BMI) through in-person or video consultations as well as medical record reviews before prescribing weight-loss tablets like Wegovy. However, the investigation found that many online providers fail to conduct these checks and instead allow patients to submit images that can be manipulated with artificial intelligence (AI).
To test the system, a reporter posed as a patient with a BMI of 39—classified as severe obesity—and approached three online pharmacies. After completing an online questionnaire, which included questions about eating disorder history, the reporter uploaded AI-edited photos to appear overweight. One pharmacy requested an online consultation, but two approved the prescription solely based on the submitted materials, sending out the medication by next-day delivery.
Prescriptions were issued at a starting dose of 1.5 milligrams, with prices around £90 for a one-month supply. The online pharmacy DoToR provided an email with instructions for safe use, while Roots Pharmacy shipped the tablets without any accompanying paperwork or guidance.
Wegovy contains Semaglutide, a drug also used to treat Type 2 diabetes. Experts warn that its misuse can have serious consequences. Jemma Cooke, nursing director at Weight Medics, emphasised the potential dangers, particularly for individuals with eating disorders, underage users, those who are underweight or at a healthy weight without medical justification, and people with certain medical conditions such as pancreatitis, thyroid cancer, diabetic retinopathy, or pregnancy.
Tom Quinn from the eating disorder charity BEAT called for stricter enforcement and penalties for pharmacies that fail to comply with legal requirements. He stressed that medications promising rapid weight loss can exacerbate harmful thoughts and behaviors in vulnerable patients or contribute to the development of eating disorders.
The investigation’s findings come in the wake of high-profile safety concerns around similar appetite-suppressing drugs. In 2024, NHS nurse Susan McGowan died after taking low-dose injections of Tirzepatide, marketed as Mounjaro, which was prescribed by a physician. Her death was attributed to multiple organ complications.
Health professionals and advocacy groups are urging for improved regulation and public education to address the risks of online slimming tablet prescriptions and prevent potential misuse among at-risk populations.